IPP Bureau
QPharma launches Ti OrderPoint 2
By IPP Bureau - August 19, 2022
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
Tavneos recommended by England’s NICE for the treatment of AAV
By IPP Bureau - August 19, 2022
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
CureVac, GSK start Phase 1 clinical study of omicron-targeting COVID-19 vaccine candidate
By IPP Bureau - August 19, 2022
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Jemincare inks licensing deal for prostate cancer drug with Roche
By IPP Bureau - August 19, 2022
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
Growing investment in biotech startups likely to make CAR-T therapies affordable in India, says GlobalData
By IPP Bureau - August 19, 2022
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
NATCO announces tentative approval to its ANDA for Trabectedin
By IPP Bureau - August 18, 2022
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
ProBioGen enters into master service agreement with NextPoint Therapeutics
By IPP Bureau - August 18, 2022
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
Sanofi updates on amcenestrant clinical development program
By IPP Bureau - August 18, 2022
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
Philips CEO Frans van Houten to step down; Roy Jakobs named successor
By IPP Bureau - August 18, 2022
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
Abbott’s blood test for concussion could predict outcomes from brain injury and inform treatment interventions
By IPP Bureau - August 18, 2022
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
Sun Pharma gets OAI from USFDA for Halol facility
By IPP Bureau - August 18, 2022
The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
FDA accepts submission of olaparib in combination with abiraterone and prednisone for prostate cancer
By IPP Bureau - August 17, 2022
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology
By IPP Bureau - August 17, 2022
Collaboration supports multiple discovery efforts, including vaccines
ResMed Q4 revenue up 4%; operating profit up 6%
By IPP Bureau - August 16, 2022
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
Short Wave Pharma signs clinical trial agreement with the Sheeba Research Fund
By IPP Bureau - August 16, 2022
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
